The role of somatostatin analogs in the management of medullary thyroid carcinoma

J Endocrinol Invest. 2003;26(8 Suppl):72-4.

Authors

G A Lupoli¹, F Fonderico, M R Fittipaldi, S Colarusso, A Panico, A Cavallo, L Di Micco, G Lupoli

Affiliation

¹ Department of Molecular and Clinical Oncology and Endocrinology, Federico II University, Naples, Italy. lupoli@unina.it

PMID: 15233217

No abstract available

Publication types

Review

MeSH terms

Antineoplastic Agents, Hormonal / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Carcinoma, Medullary / drug therapy*
Humans
Immunologic Factors / administration & dosage
Interferon-alpha / administration & dosage
Octreotide / administration & dosage
Peptides, Cyclic / administration & dosage
Somatostatin / administration & dosage
Somatostatin / analogs & derivatives*
Thyroid Neoplasms / drug therapy*

Substances

Antineoplastic Agents, Hormonal
Immunologic Factors
Interferon-alpha
Peptides, Cyclic
lanreotide
Somatostatin
Octreotide